Clara Unger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Clara Unger has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Agnieszka Rybak-Wolf
Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
1 shared publication - Andreas C. Hocke
Department of Infectious Diseases, Respiratory Medicine and Critical Care Medicine, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
1 shared publication - Andreas Thiel
Der Simulierte Mensch, a science framework of Technische Universität Berlin and Charité – Universitätsmedizin Berlin, Berlin, Germany
1 shared publication Beate Kruse
Si-M/“Der Simulierte Mensch,” a Science Framework of Technische Universität Berlin and Charité – Universitätsmedizin Berlin, Berlin, Germany
1 shared publication- Birgit Sawitzki
Preprint Club, Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany
1 shared publication - Christian Drosten
Institute of Virology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health
1 shared publication
Latest Publications
- Open Access
New disease models for investigating SynGAP1-related disorder (SRD) caused by a common heterozygous nonsense SYNGAP1 mutation
Background: Mutations in the SYNGAP1 gene cause SynGAP1-related disorder (SRD), a severe neurodevelopmental disorder marked by intellectual disability, epilepsy, ataxia, autism spectrum disorder, and global developmental delay. Studies in mouse models of SRD show that restoration of SynGAP1 expression in adult animals improves memory and seizure threshold, highlighting the disorder’s potential for successful therapeutic intervention over the entire lifetime. Methods: We established an integrated disease-modelling pipeline centered on the recurrent SYNGAP1 c.427C>T, p.(Arg143Ter), nonsense mutation, integrating neuronal and organoid models from patient-derived human induced pluripotent stem cells (hiPSCs) and a humanized knock-in mouse line to investigate mutation-specific disease phenotype across complementary experimental systems. Results: We demonstrate that the c.427C>T mutation leads to a reduction of SynGAP1 protein levels and a corresponding dysregulation of Ras/ERK signaling in human forebrain organoids as well as in the mouse model system. In vivo , mice harboring the c.427C>T mutation show a hyperactivity phenotype that corresponds well to phenotypic features seen in patients such as absence of fear, hyperactive behavior and a strong urge to investigate the immediate surroundings. Conclusion: Taken together, our molecular and behavioral data in the humanized mouse are in line with studies on conventional heterozygous SynGAP1 knockout models, underscoring the relevance of these new disease models for further investigations into disease pathology. Moreover, with the three models described here, we present a translational platform that enables the development and evaluation of gene therapies that target disease-causing single nucleotide variations in the SYNGAP1 coding sequence.
Open AccessNew disease models for investigating SynGAP1-related disorder (SRD) caused by a common heterozygous nonsense SYNGAP1 mutation
Background: Mutations in the SYNGAP1 gene cause SynGAP1-related disorder (SRD), a severe neurodevelopmental disorder marked by intellectual disability, epilepsy, ataxia, autism spectrum disorder, and global developmental delay. Studies in mouse models of SRD show that restoration of SynGAP1 expression in adult animals improves memory and seizure threshold, highlighting the disorder’s potential for successful therapeutic intervention over the entire lifetime. Methods: We established an integrated disease-modelling pipeline centered on the recurrent SYNGAP1 c.427C>T, p.(Arg143Ter), nonsense mutation, integrating neuronal and organoid models from patient-derived human induced pluripotent stem cells (hiPSCs) and a humanized knock-in mouse line to investigate mutation-specific disease phenotype across complementary experimental systems. Results: We demonstrate that the c.427C>T mutation leads to a reduction of SynGAP1 protein levels and a corresponding dysregulation of Ras/ERK signaling in human forebrain organoids as well as in the mouse model system. In vivo , mice harboring the c.427C>T mutation show a hyperactivity phenotype that corresponds well to phenotypic features seen in patients such as absence of fear, hyperactive behavior and a strong urge to investigate the immediate surroundings. Conclusion: Taken together, our molecular and behavioral data in the humanized mouse are in line with studies on conventional heterozygous SynGAP1 knockout models, underscoring the relevance of these new disease models for further investigations into disease pathology. Moreover, with the three models described here, we present a translational platform that enables the development and evaluation of gene therapies that target disease-causing single nucleotide variations in the SYNGAP1 coding sequence.
- Top Cited PapersOpen Access
- 8 October 2021
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 374 (6564) , 171-+
Cross-reactive CD4 + T cells enhance SARS-CoV-2 immune responses upon infection and vaccination
Cross-reactive T cells aid in the fight: There is mounting evidence that immunological memory after infection with seasonal human coronaviruses (hCoVs) contributes to cross-protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Loyal et al . identified a universal immunodominant coronavirus peptide found within the fusion peptide domain of coronavirus spike protein. This peptide is recognized by CD4 + T cells in 20% of unexposed individuals, more than 50% of SARS-CoV-2 convalescents, and 97% of subjects treated with the Pfizer–BioNTech COVID-19 vaccine. Although ubiquitous, these coronavirus-reactive T cells decreased with age, which may explain in part the increased susceptibility of elderly people to COVID-19. —STS
- 8 October 2021
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 374 (6564) , 171-+
Top Cited PapersOpen AccessCross-reactive CD4 + T cells enhance SARS-CoV-2 immune responses upon infection and vaccination
Cross-reactive T cells aid in the fight: There is mounting evidence that immunological memory after infection with seasonal human coronaviruses (hCoVs) contributes to cross-protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Loyal et al . identified a universal immunodominant coronavirus peptide found within the fusion peptide domain of coronavirus spike protein. This peptide is recognized by CD4 + T cells in 20% of unexposed individuals, more than 50% of SARS-CoV-2 convalescents, and 97% of subjects treated with the Pfizer–BioNTech COVID-19 vaccine. Although ubiquitous, these coronavirus-reactive T cells decreased with age, which may explain in part the increased susceptibility of elderly people to COVID-19. —STS